Physician profile
Sevan Sagherian
NPI 1790253300
$1,374.39
in general payments reported to CMS, 2019-2025
10 companies · $981 in 2025
The $981 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $20.70 · 2024: $263 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $262.87 | 2024 | |
| Novo Nordisk INC | $219.79 | 2025 | Ozempic |
| Insulet Corporation | $150.27 | 2025 | Omnipod |
| Cequr Corporation | $149.84 | 2025 | Cequr Simplicity |
| Abbott Laboratories | $133.27 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $122.41 | 2022-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals Lp | $109.95 | 2021 | |
| Lilly USA, LLC | $108.80 | 2025 | Mounjaro |
| Tandem Diabetes Care, INC. | $95.05 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $22.14 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevan Sagherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.